• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    XOMA Royalty Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    5/30/25 4:30:28 PM ET
    $XOMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $XOMA alert in real time by email
    8-K
    XOMA Royalty Corp --12-31 0000791908 false 0000791908 2025-05-28 2025-05-28 0000791908 us-gaap:CommonStockMember 2025-05-28 2025-05-28 0000791908 us-gaap:SeriesAPreferredStockMember 2025-05-28 2025-05-28 0000791908 dei:AdrMember 2025-05-28 2025-05-28
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event Reported): May 28, 2025

     

     

    XOMA ROYALTY CORPORATION

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Nevada   001-39801   52-2154066

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

      (I.R.S. Employer
    Identification Number)

    2200 Powell Street, Suite 310, Emeryville, California 94608

    (Address of Principal Executive Offices) (Zip Code)

    (510) 204-7200

    (Registrant’s telephone number, including area code)

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, $0.0075 par value   XOMA   The Nasdaq Global Market
    8.625% Series A Cumulative Perpetual Preferred Stock, par value $0.05 per share   XOMAP   The Nasdaq Global Market
    Depositary Shares (each representing 1/1000th interest in a share of 8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share)   XOMAO   The Nasdaq Global Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    On May 21, 2025, XOMA Royalty Corporation (the “Company”) convened its 2025 Annual Meeting of Stockholders, which was adjourned until May 28, 2025 (the “Annual Meeting”), at which point the polls were closed on the proposals contained in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 15, 2025 (the “Proxy Statement”). As of the close of business on March 31, 2025, the record date for the Annual Meeting, there were 11,952,889 shares of the Company’s common stock issued and outstanding.

     

    Item 3.03

    Material Modification to Rights of Shareholders.

    At the Annual Meeting, the Company’s stockholders approved the proposed reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”) by means of a plan of conversion (the “Plan of Conversion”), as described in the Proxy Statement. Pursuant to the Plan of Conversion, the Company effected the Reincorporation as of May 30, 2025 by filing: (i) a certificate of conversion with the Secretary of State of the State of Delaware, (ii) articles of conversion with the Nevada Secretary of State, and (iii) articles of incorporation with the Nevada Secretary of State (the “Nevada Charter”). The Company also adopted new bylaws (the “Nevada Bylaws”) to reflect the Reincorporation.

    At the effective time of the Reincorporation:

     

      •  

    The Company’s state of incorporation changed from the State of Delaware to the State of Nevada.

     

      •  

    The affairs of the Company ceased to be governed by the Delaware General Corporation Law and the Company’s existing certificate of incorporation and bylaws, and instead, became governed by the Nevada Revised Statutes, the Nevada Charter and the Nevada Bylaws.

     

      •  

    The Company continues to be the same entity and continues with all of the same rights, privileges and powers.

     

      •  

    The Company continues to have the same name, possesses all of the same properties, continues with all of the same debts, liabilities and obligations, and continues with the same officers and directors as immediately prior to the Reincorporation.

     

      •  

    Each outstanding share of common stock of the Delaware corporation shall represent a share of the Nevada corporation and each outstanding certificate representing shares of the Delaware corporation shall be deemed an equivalent certificate representing shares of the Nevada corporation.

     

      •  

    The Company’s employee benefit and incentive plans continued, and each option, equity award or other right issued under such plans by the Delaware corporation automatically converted into an option, equity award or right to purchase or receive the same number of shares of common stock of the Nevada corporation, at the same price per share, upon the same terms and subject to the same conditions as before the Reincorporation. All employee benefit and incentive plans of the Delaware corporation continue to be employee benefit and incentive plans of the Nevada corporation.

    The Reincorporation did not result in any change in the business, physical location, management, assets, liabilities or net worth of the Company, nor did it result in any change in location of the Company’s current employees, including management. The Reincorporation did not affect any of the Company’s material contracts with any third parties, and the Company’s rights and obligations under those material contractual arrangements will continue to be the rights and obligations of the Company after the Reincorporation. The daily business operations of the Company will continue as they were conducted prior to the Reincorporation. The consolidated financial condition and results of operations of the Company immediately after consummation of the Reincorporation remain the same as immediately before the Reincorporation.

    Certain rights of the Company’s stockholders were changed as a result of the Reincorporation. A more detailed description of the Plan of Conversion, Nevada Charter, and Nevada Bylaws, and the effects of the Reincorporation, is set forth in Proposal 3 of the Proxy Statement, and the description contained therein is incorporated herein by reference. Copies of the Plan of Conversion, the Nevada Charter and the Nevada Bylaws are attached hereto as Exhibit 2.1, Exhibit 3.1 and Exhibit 3.2, respectively, and are incorporated by reference herein.


    Item 5.02

    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    At the Annual Meeting, the Company’s stockholders approved the Company’s Amended and Restated 2010 Long Term Incentive and Stock Award Plan (as so amended, the “Plan”), which increases the shares of common stock available for issuance under the Plan by 880,000 shares, prohibits payment of dividends and dividend equivalents on unvested awards and makes other ministerial changes.

    For additional information regarding the Plan, please refer to the heading “Summary of the Proposed A&R Plan” contained in Proposal 5 of the Proxy Statement.

    The foregoing description and the summary contained in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the Plan, which is filed hereto as Exhibit 10.1.

     

    Item 5.03

    Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

    The information set forth under Item 3.03 is incorporated by reference into this Item 5.03.

     

    Item 5.07

    Submission of Matters to a Vote of Security Holders.

    At the Annual Meeting, each of the Company’s director nominees was elected and each of the other proposals voted on was approved. The final voting results are set forth below:

     

           Votes
    For
         Votes
    Withheld
         Broker
    Non-Votes
     

    Proposal 1. Election of Director Nominees

     

            

    •  Owen Hughes

       

         8,545,322        23,576        439,827  

    •  Jack L. Wyszomierski

       

         8,543,778        25,120        439,827  

    •  Heather L. Franklin

       

         8,148,838        420,060        439,827  

    •  Natasha Hernday

       

         8,470,360        98,538        439,827  

    •  Barbara Kosacz

       

         8,533,353        35,545        439,827  

    •  Joseph M. Limber

       

         8,242,298        326,600        439,827  

    •  Matthew D. Perry

       

         7,470,489        1,098,409        439,827  
         Votes
    For
         Votes
    Against
         Abstentions      Broker
    Non-Votes
     

    Proposal 2. Ratification of Selection of Deloitte & Touche LLP as Independent Auditor

         8,986,825        2,222        19,678        0  
         Votes
    For
         Votes
    Against
         Abstentions      Broker
    Non-Votes
     

    Proposal 3. Approval of the Reincorporation of the Company from the State of Delaware to the State of Nevada by Conversion

         6,010,857        2,548,042        9,999        439,827  
         Votes
    For
         Votes
    Against
         Abstentions      Broker
    Non-Votes
     

    Proposal 4. Approval of Proposal to Authorize the Board to Unilaterally Amend the By-laws

         8,412,002        120,508        36,388        439,827  


         Votes
    For
       Votes
    Against
       Abstentions    Broker
    Non-Votes

    Proposal 5. Approval of the Amended and Restated 2010 Long Term Incentive and Stock Award Plan

       8,146,010    409,056    13,832    439,827

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits.

     

    Number

      

    Description of Document

     2.1    Plan of Conversion of XOMA Royalty Corporation
     3.1    Nevada Articles of Incorporation of XOMA Royalty Corporation
     3.2    Nevada Bylaws of XOMA Royalty Corporation
    10.1    Amended and Restated 2010 Long Term Incentive and Stock Award Plan.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document).


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        XOMA ROYALTY CORPORATION
    Date: May 30, 2025     By:  

    /s/ THOMAS BURNS

          Thomas Burns
          Senior Vice President, Finance and Chief Financial Officer
    Get the next $XOMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XOMA

    DatePrice TargetRatingAnalyst
    4/17/2025$35.00Buy
    The Benchmark Company
    4/29/2024$40.00Outperform
    Leerink Partners
    10/8/2021$56.00 → $69.00Buy
    HC Wainwright & Co.
    9/9/2021$60.00 → $56.00Buy
    Aegis Capital
    9/7/2021$22.00Outperform → Neutral
    Wedbush
    9/7/2021$22.00Neutral → Underperform
    Wedbush
    6/29/2021$60.00Buy
    Aegis Capital
    More analyst ratings

    $XOMA
    Leadership Updates

    Live Leadership Updates

    See more
    • XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

      Earned $9 million milestone upon U.S. Food and Drug Administration's approval of Day One's OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in non-dilutive capital to XOMA's balance sheet Expanded the commercial royalty and milestone portfolio with the acquisitions of economic interests in DSUVIA® (sufentanil sublingual tablet) and XACIATO™ (clindamycin phosphate) vaginal gel 2%, as well as two Phase 3 assets Launched XOMA's first stock repurchase program for up to $50 million EMERYVILLE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royal

      5/9/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actym Therapeutics Appoints Thomas Smart as CEO

      BERKELEY, Calif., April 24, 2024 /PRNewswire/ -- Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointment of Thomas Smart as Chief Executive Officer. With 25 years of experience in senior management and executive roles as well as Board of Directors positions across the biopharmaceutical industry, Mr. Smart brings a significant track record in leading organizations through value-building transitions. His breadth of expertise will be highly beneficial to Actym as it prepares to enter clinical evaluation of its lead candidate, ACTM-838, later this year.

      4/24/24 9:00:00 AM ET
      $ANAB
      $PGEN
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Names Owen Hughes as Chief Executive Officer and Appoints Jack L. Wyszomierski as Chairman of the Board of Directors

      EMERYVILLE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today the Board of Directors has named Owen Hughes as Chief Executive Officer and Jack L. Wyszomierski as Chairman of the Board.  Mr. Hughes has served as XOMA's Executive Chairman and Interim Chief Executive Officer since January 1, 2023. "The rest of the Board and I have been impressed with Owen's leadership over the past year and his vision to establish XOMA as the premiere biotech royalty aggregator.  I am looking forward to working closely with Owen and the team to further accelerate the Company's growth and maximize value for all XOMA stockholders," stated

      1/8/24 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

      SC 13G/A - XOMA Corp (0000791908) (Subject)

      2/9/24 10:05:21 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by XOMA Corporation (Amendment)

      SC 13D/A - XOMA Corp (0000791908) (Subject)

      1/16/24 5:22:40 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by XOMA Corporation (Amendment)

      SC 13G/A - XOMA Corp (0000791908) (Subject)

      2/9/23 12:46:50 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Kosacz Barbara was granted 5,971 shares (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:48:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Wyszomierski Jack L was granted 5,971 shares, increasing direct ownership by 48% to 18,504 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:48:15 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Limber Joseph M

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      5/23/25 4:47:58 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

      EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million. "This transaction further builds the potential of XOMA Royalty's late-stage royalty portfolio by increasing our economics in a pr

      5/27/25 8:01:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference

      EMERYVILLE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today its Chief Executive Officer, Owen Hughes, and Chief Investment Officer, Brad Sitko, will be featured speakers at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference being held May 13, 2025. Mr. Hughes and Mr. Sitko will participate in a fireside chat at 2:30 PM ET.  Mr. Hughes will join the "Pros and Cons of Royalty Model – Especially in Current Financing Environment" panel discussion at 4:00 PM ET.  Mr. Sitko will participate in the "Development-Stage Companies – Where do Royalty and Tech Platforms Play Fit?" panel at 5:00 PM ET.  

      5/7/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Financials

    Live finance-specific insights

    See more
    • XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million

      EMERYVILLE, Calif. and LUND, Sweden, May 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced XOMA Royalty has purchased the future mezagitamab (TAK-079) royalty and milestone interests held by BioInvent for USD $20 million at closing, with a total transaction of up to USD $30 million. "This transaction further builds the potential of XOMA Royalty's late-stage royalty portfolio by increasing our economics in a pr

      5/27/25 8:01:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Completes Sale of Kinnate Pipeline Assets

      XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024.

      4/14/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • XOMA Royalty Declares Quarterly Preferred Stock Dividends

      EMERYVILLE, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty's Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (NASDAQ:XOMAP) shall receive a cash dividend equal to $0.53906 per share.  Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty's 8.375% Series B Cumulative Perpetual Preferred Stock (NASDAQ:XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share. The preferred dividends will be paid on or about April 15, 2025, to respe

      3/20/25 7:30:00 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Investment Officer Sitko Bradley bought $49,400 worth of Depositary Shares - 8.375% Series B Cumulative Stock (2,000 units at $24.70), increasing direct ownership by 66% to 5,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/9/25 4:44:30 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Limber Joseph M bought $504,504 worth of Depositary Shares - 8.375% Series B Cumulative Stock (20,000 units at $25.23) and bought $255,640 worth of 8.625% Series A Cumulative Perpetual Preferred Stock (10,000 units at $25.56) (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/7/25 4:39:59 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Investment Officer Sitko Bradley bought $19,980 worth of shares (1,000 units at $19.98) and bought $6,221 worth of Depositary Shares - 8.375% Series B Perpetual Preferred (245 units at $25.39), decreasing direct ownership by 71% to 3,045 units (SEC Form 4)

      4 - XOMA Royalty Corp (0000791908) (Issuer)

      4/2/25 4:30:27 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    SEC Filings

    See more
    • XOMA Royalty Corporation filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

      8-K - XOMA Royalty Corp (0000791908) (Filer)

      5/30/25 4:30:28 PM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by XOMA Royalty Corporation

      10-Q - XOMA Royalty Corp (0000791908) (Filer)

      5/13/25 7:45:36 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by XOMA Royalty Corporation

      8-K - XOMA Royalty Corp (0000791908) (Filer)

      5/13/25 7:45:25 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $XOMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Benchmark Company initiated coverage on XOMA Royalty Corporation with a new price target

      The Benchmark Company initiated coverage of XOMA Royalty Corporation with a rating of Buy and set a new price target of $35.00

      4/17/25 8:34:06 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on XOMA with a new price target

      Leerink Partners initiated coverage of XOMA with a rating of Outperform and set a new price target of $40.00

      4/29/24 8:01:47 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on XOMA with a new price target

      HC Wainwright & Co. reiterated coverage of XOMA with a rating of Buy and set a new price target of $69.00 from $56.00 previously

      10/8/21 6:18:28 AM ET
      $XOMA
      Biotechnology: Pharmaceutical Preparations
      Health Care